Takeaim lymphoma: An open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies Meeting Abstract
| Authors: | Grommes, C.; Tun, H.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Regales, L.; Zhao, W.; Lane, M.; Wang, C.; von Roemeling, R.; Isufi, I.; Leslie, L. A.; Nowakowski, G. S. |
| Abstract Title: | Takeaim lymphoma: An open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4497 |
| Language: | English |
| ACCESSION: | WOS:001159740307243 |
| DOI: | 10.1182/blood-2023-189746 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
